Preferred Label : therapeutic use;
CISMeF acronym : TU;
Origin ID : Q000627;
UMLS CUI : C0039795;
Automatic exact mappings (from CISMeF team)
- False automatic mappings
- Metaterm(s)
- See also (suggested by CISMeF)
- Semantic type(s)
https://www.has-sante.fr/jcms/p_3490820/fr/opdualag-nivolumab/relatlimab-melanome
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug combinations
relatlimab
nivolumab and relatlimab
Nivolumab
Antineoplastic Agents, Immunological
infusions, intravenous
Unresectable Cutaneous Melanoma
adult
adolescent
PD-L1 Expression Less than 1 Percent
Advanced Cutaneous Melanoma
evaluation of the transparency committee
melanoma
---
https://www.has-sante.fr/jcms/p_3490827/fr/yselty-linzagolix-choline-fibromes-uterins
2024
false
false
false
France
administration, oral
adult
linzagolix
receptors, LHRH
evaluation of the transparency committee
Linzagolix Choline
fibroid uterus
linzagolix
leiomyoma
---
https://www.has-sante.fr/jcms/p_3490824/fr/crysvita-burosumab-hypophosphatemie-liee-a-l-x
2024
false
false
false
France
child
adolescent
treatment outcome
insurance, health, reimbursement
rickets, X-Linked hypophosphatemic
burosumab
injections, subcutaneous
antibodies, monoclonal, humanized
evaluation of the transparency committee
burosumab
familial hypophosphatemic rickets
X-Linked Dominant Hypophosphatemic Rickets
---
https://ansm.sante.fr/tableau-marr/mecasermine
2024
false
false
false
France
French
risk management
mecasermin
mecasermin
mecasermin
Drug-Related side effects and adverse reactions
patient education handout
guidelines for drug use
mecasermin
hypoglycemia
injections, subcutaneous
---
https://www.has-sante.fr/jcms/p_3492656/fr/scyova-foslevodopa/foscarbidopa-maladie-de-parkinson
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug combinations
Foscarbidopa
Foslevodopa
antiparkinson agents
infusions, intravenous
pharmaceutical solutions
foslevodopa and decarboxylase inhibitor
evaluation of the transparency committee
parkinson disease
---
https://www.has-sante.fr/jcms/p_3492662/fr/ciclopirox-substipharm-ciclopirox-antifongique-a-usage-topique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, cutaneous
Medicated Nail Lacquer Dosage Form
ciclopirox
onychomycosis
evaluation of the transparency committee
Ciclopirox
antifungal agents
---
https://www.has-sante.fr/jcms/p_3492683/fr/kynmobi-chlorhydrate-d-apomorphine-maladie-de-parkinson
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, sublingual
apomorphine
adult
dopamine agonists
Sublingual Film Dosage Form
evaluation of the transparency committee
apomorphine
parkinson disease
apomorphine hydrochloride
---
https://ansm.sante.fr/tableau-acces-derogatoire/itraconazole
2024
false
false
false
France
French
itraconazole
guidelines for drug use
administration, oral
tinea
child
microsporum
antifungal agents
itraconazole
continuity of patient care
---
https://www.cbip.be/fr/articles/4262?folia=4259
2024
false
false
false
Belgium
French
journal article
antidepressive agents
chronic pain
Systematic Reviews as Topic
---
https://www.has-sante.fr/jcms/p_3491848/fr/giapreza-acetate-d-angiotensine-ii-hypotension-refractaire-dans-les-chocs-distributifs
2024
false
false
false
France
Giapreza
angiotensin II
insurance, health, reimbursement
treatment outcome
vasoconstrictor agents
shock
infusions, intravenous
shock, septic
Distributive shock
adult
Product containing only angiotensin II in parenteral dose form (medicinal product
form)
evaluation of the transparency committee
Angiotensin II Acetate
angiotensin II
hypotension
---
https://ansm.sante.fr/actualites/avis-de-lansm-du-19-12-2023-sur-le-medicament-casgevy-le-cadre-dune-demande-daap
2024
false
false
false
France
French
drug information
exagamglogene autotemcel
Exagamglogene Autotemcel
Transfusion Dependent Beta Thalassemia
---
https://www.has-sante.fr/jcms/p_3494990/fr/orserdu-elacestrant-cancer-du-sein
2024
false
false
false
France
elacestrant
insurance, health, reimbursement
treatment outcome
postmenopause
Activating ESR1 Gene Mutation
Locally Advanced Estrogen Receptor-Positive Breast Carcinoma
Metastatic Estrogen Receptor-Positive Breast Carcinoma
HER2/Neu Negative
administration, oral
selective estrogen receptor modulators
evaluation of the transparency committee
elacestrant
breast neoplasms
---
https://ansm.sante.fr/actualites/decision-du-13-02-2024-cadre-de-prescription-compassionnelle-de-tibsovo-ivosidenib-250mg-comprime-pellicule
https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2024
false
false
false
France
French
drug information
administration, oral
ivosidenib
adult
glioma
guidelines for drug use
continuity of patient care
Unresectable Low Grade Glioma
Refractory Low Grade Glioma
IDH1 Gene Mutation
ivosidenib
---
https://www.cbip.be/fr/articles/4263?folia=4259
2024
false
false
false
Belgium
French
journal article
drug information
glucocorticoids
administration, oral
Long-term current use of drug therapy (situation)
---
https://www.has-sante.fr/jcms/p_3495284/fr/tak-755-apadamtase-alfa-purpura-thrombotique-thrombocytopenique-congenital-pttc
2024
false
false
false
France
enzyme replacement therapy
congenital thrombotic thrombocytopenic purpura
adolescent
adult
enzymes
evaluation of the transparency committee
purpura, thrombotic thrombocytopenic
Apadamtase Alfa
---
https://ansm.sante.fr/tableau-acces-derogatoire/casgevy
2024
false
false
false
France
French
biological products
exagamglogene autotemcel
Exagamglogene Autotemcel
summary of product characteristics
package leaflet
guidelines for drug use
risk management
beta-Thalassemia
Transfusion Dependent Beta Thalassemia
adolescent
adult
Cell positive for CD34 antigen (cell)
infusions, intravenous
---
https://ansm.sante.fr/tableau-acces-derogatoire/bylvay
2024
false
false
false
France
French
insurance, health, reimbursement
odevixibat
odevixibat
summary of product characteristics
package leaflet
guidelines for drug use
infant
child
pruritus
cholestatic pruritus in Alagille syndrome
alagille syndrome
---
https://ansm.sante.fr/tableau-marr/pirfenidone
2024
false
false
false
France
French
guidelines for drug use
risk management
pirfenidone
pirfenidone
administration, oral
patient education handout
photosensitization
Drug-induced photosensitivity (disorder)
pirfenidone
Chemical and Drug Induced Liver Injury
continuity of patient care
liver function tests
Drug-Related side effects and adverse reactions
---
https://ansm.sante.fr/actualites/tensions-dapprovisionnement-en-corgard-80-mg-nadolol-ce-medicament-doit-etre-reserve-a-certains-patients-atteints-de-troubles-du-rythme-dorigine-genetique
2024
false
false
false
France
French
nadolol
drug information
guideline
patient education handout
Genetic cardiac rhythm disease
arrhythmias, cardiac
nadolol
arrhythmias, cardiac
---
https://ansm.sante.fr/tableau-marr/eculizumab-2
2024
false
false
false
France
French
risk management
eculizumab
eculizumab
eculizumab
guidelines for drug use
patient education handout
patients guideline
antibiotic prophylaxis
infusions, intravenous
Infections
sepsis
Drug-Related side effects and adverse reactions
meningococcal infections
vaccination
meningococcal vaccines
---
https://ansm.sante.fr/tableau-acces-derogatoire/momelotinib
2024
false
false
false
France
French
drug information
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
---
https://ansm.sante.fr/tableau-acces-derogatoire/rybrevant
2024
false
false
false
France
French
summary of product characteristics
amivantamab-vmjw
Antineoplastic Agents, Immunological
amivantamab
advanced non-small cell lung cancer with activating epidermal growth factor receptor
exon 20 insertion mutations
carcinoma, non-small-cell lung
guidelines for drug use
package leaflet
---
https://www.has-sante.fr/jcms/p_3443053/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2
2024
false
false
false
France
adult
treatment outcome
insurance, health, reimbursement
Unresectable HER2-Positive Breast Carcinoma
Metastatic HER2-Positive Breast Carcinoma
neoplasm metastasis
trastuzumab deruxtecan
guidelines for drug use
Antineoplastic Agents, Immunological
infusions, intravenous
evaluation of the transparency committee
breast neoplasms
trastuzumab deruxtecan
Trastuzumab
---
https://www.has-sante.fr/jcms/p_3423139/fr/spevigo-spesolimab-psoriasis-pustuleux-generalise-ppg
2024
false
false
false
France
Generalized pustular psoriasis
spesolimab
adult
treatment outcome
insurance, health, reimbursement
infusions, intravenous
evaluation of the transparency committee
psoriasis
spesolimab
---
https://ansm.sante.fr/tableau-acces-derogatoire/maribavir
2024
false
false
false
France
French
maribavir
drug information
administration, oral
maribavir
cytomegalovirus infections
adult
Refractory Cytomegalovirus Infection
antiviral agents
---
https://www.has-sante.fr/jcms/p_3412521/fr/abecma-idecabtagene-vicleucel-myelome-multiple
https://www.has-sante.fr/jcms/p_3412521/en/abecma-idecabtagene-vicleucel-myelome-multiple
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
idecabtagene vicleucel
infusions, intravenous
Antineoplastic Agents, Immunological
evaluation of the transparency committee
idecabtagene vicleucel
multiple myeloma
---
https://ansm.sante.fr/tableau-acces-derogatoire/upstaza
2024
false
false
false
France
French
Eladocagene Exuparvovec
drug information
infant
Aromatic-L-Amino-Acid decarboxylases
Aromatic-L-Amino-Acid Decarboxylase
aromatic amino acid decarboxylase deficiency
---
https://ansm.sante.fr/tableau-acces-derogatoire/tecartus-0-4-2-x-108-cellules-dispersion-pour-perfusion
2024
false
false
false
France
French
brexucabtagene autoleucel
drug information
Refractory B Acute Lymphoblastic Leukemia
precursor cell lymphoblastic Leukemia-Lymphoma
brexucabtagene autoleucel
gene therapy
---
https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2024
false
false
false
France
French
administration, oral
summary of product characteristics
cholangiocarcinoma
guidelines for drug use
leukemia, myeloid, acute
glioma
myelodysplastic syndromes
antineoplastic agents
ivosidenib
ivosidenib
neoplasm metastasis
package leaflet
---
https://ansm.sante.fr/tableau-acces-derogatoire/ripretinib-50-mg-comprime
2024
false
false
false
France
French
administration, oral
ripretinib
ripretinib
drug information
gastrointestinal stromal tumors
Refractory Malignant Gastrointestinal Stromal Tumor
adult
antineoplastic agents
---
https://ansm.sante.fr/tableau-acces-derogatoire/sotrovimab-500-mg-solution-a-diluer-pour-perfusion-intraveineuse-xevudy
2024
false
false
false
France
French
infusions, intravenous
drug information
adult
adolescent
COVID-19
sotrovimab
sotrovimab
---
https://ansm.sante.fr/tableau-marr/dabigatran
2024
false
false
false
France
French
guidelines for drug use
risk management
Dabigatran
Dabigatran
dabigatran etexilate
administration, oral
antithrombins
antithrombins
continuity of patient care
hemorrhage
risk
adult
child
---
https://ansm.sante.fr/tableau-acces-derogatoire/keytruda-25-mg-ml-solution-a-diluer-pour-perfusion#
2024
false
false
false
France
French
drug information
triple negative breast neoplasms
pembrolizumab
pembrolizumab
summary of product characteristics
package leaflet
guidelines for drug use
adult
Early Stage Triple-Negative Breast Carcinoma
Locally Advanced Triple-Negative Breast Carcinoma
inflammatory breast neoplasms
Antineoplastic Agents, Immunological
endometrial neoplasms
clear cell renal cell carcinoma
renal cell carcinoma at increased risk of recurrence following nephrectomy, or following
nephrectomy and resection of metastatic lesions
---
https://ansm.sante.fr/tableau-acces-derogatoire/idefirix
2024
false
false
false
France
French
infusions, intravenous
imlifidase
Imlifidase
kidney transplantation
Anti-HLA hyperimmunization
drug information
---
https://ansm.sante.fr/tableau-acces-derogatoire/maralixibat
2024
false
false
false
France
French
drug information
insurance, health, reimbursement
maralixibat
Maralixibat Chloride
administration, oral
maralixibat chloride
alagille syndrome
pruritus
Cholestatic pruritus (disorder)
---
https://ansm.sante.fr/tableau-acces-derogatoire/vutrisiran
2024
false
false
false
France
French
Vutrisiran
drug information
amyloidosis, hereditary, Transthyretin-Related
vutrisiran
---
https://www.has-sante.fr/jcms/p_3390379/fr/ciclograft-ciclosporine-greffe-de-cornee
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
graft rejection
drug therapy, combination
risk factors
guidelines for drug use
ophthalmic solutions
administration, ophthalmic
immunosuppressive agents
evaluation of the transparency committee
corneal transplantation
cyclosporine
---
https://ansm.sante.fr/tableau-acces-derogatoire/adcetris-50-mg-poudre-pour-solution-a-diluer-pour-perfusion
2024
false
false
false
France
French
continuity of patient care
guideline
hodgkin disease
child
adolescent
adult
antineoplastic combined chemotherapy protocols
brentuximab vedotin
Brentuximab Vedotin
infusions, intravenous
---
https://ansm.sante.fr/tableau-acces-derogatoire/berinert-500-ui-mg-poudre-et-solvant-pour-solution-injectable-perfusion
2024
false
false
false
France
French
complement C1 inhibitor protein
guidelines for drug use
continuity of patient care
salvage therapy
graft rejection
Humoral rejection
heart transplantation
kidney transplantation
lung transplantation
infusions, intravenous
complement C1 inhibitor protein
technical report
---
https://ansm.sante.fr/tableau-marr/tetradecyl-sulfate-de-sodium
2024
false
false
false
France
French
risk management
guidelines for drug use
continuity of patient care
sodium tetradecyl sulfate
sclerosing solutions
sodium tetradecyl sulfate
sodium tetradecyl sulfate
injections, intravenous
sclerotherapy
---
https://ansm.sante.fr/tableau-acces-derogatoire/kaftrio-75-mg-50-mg-100-mg-comprime-pellicule-kalydeco-150-mg-comprime-pellicule
2024
false
false
false
France
French
cystic fibrosis
guidelines for drug use
continuity of patient care
drug therapy, combination
administration, oral
ivacaftor, tezacaftor and elexacaftor
elexacaftor, ivacaftor, tezacaftor drug combination
ivacaftor
tezacaftor
elexacaftor
adult
adolescent
ivacaftor
trikafta
drug combinations
drug information
---
https://ansm.sante.fr/tableau-atu-rtu/wegovy-solution-injectable-en-stylo-prerempli
2024
false
false
false
France
French
drug information
semaglutide
adult
obesity
weight loss
body mass index
risk factors
comorbidity
summary of product characteristics
package leaflet
guidelines for drug use
patients guideline
continuity of patient care
pregnancy
injections, subcutaneous
---
https://ansm.sante.fr/tableau-marr/ponesimod
2024
false
false
false
France
French
risk management
ponesimod
ponesimod
administration, oral
ponesimod
ponvory
guidelines for drug use
patients guideline
pregnancy
continuity of patient care
ponesimod
adult
multiple sclerosis, relapsing-remitting
drug monitoring
immunosuppressive agents
immunosuppressive agents
immunosuppressive agents
---
https://ansm.sante.fr/tableau-acces-derogatoire/ciclograft-20mg-ml-collyre-en-solution-en-recipient-unidose
2024
false
false
false
false
France
French
package leaflet
cyclosporine
administration, ophthalmic
guidelines for drug use
corneal transplantation
graft rejection
summary of product characteristics
---
https://ansm.sante.fr/tableau-marr/nalmefene
2024
false
false
false
France
French
risk management
nalmefene
nalmefene
guidelines for drug use
patient education handout
administration, oral
patient compliance
patients guideline
alcohol drinking
continuity of patient care
nalmefene
alcoholism
adult
algorithms
Psychosocial Intervention
---
https://ansm.sante.fr/tableau-atu-rtu/primaquine-sanofi-15-mg-comprime-pellicule
2024
false
false
false
France
French
primaquine
summary of product characteristics
package leaflet
guidelines for drug use
primaquine
malaria, vivax
Ovale malaria (disorder)
recurrence
administration, oral
antimalarials
pneumonia, pneumocystis
---
https://ansm.sante.fr/tableau-marr/tolvaptan
2024
false
false
false
France
French
risk management
Tolvaptan
Tolvaptan
administration, oral
tolvaptan
polycystic kidney, autosomal dominant
continuity of patient care
liver diseases
pregnancy
guidelines for drug use
patients guideline
patient education handout
---
https://ansm.sante.fr/tableau-acces-derogatoire/selpercatinib-20-40-et-80mg-gelule
2024
false
false
false
France
French
selpercatinib
administration, oral
carcinoma, non-small-cell lung
advanced RET fusion-positive non-small cell lung cancer
Product containing only selpercatinib in oral dose form (medicinal product form)
drug information
selpercatinib
pyrazoles
pyridines
---
https://ansm.sante.fr/tableau-atu-rtu/abecma-260-500-x-106-cellules-dispersion-pour-perfusion
2024
false
false
false
France
French
guidelines for drug use
Idecabtagene Vicleucel
Idecabtagene Vicleucel
gene therapy
immunotherapy, adoptive
adult
multiple myeloma
recurrence
Refractory Multiple Myeloma
idecabtagene vicleucel
idecabtagene vicleucel
Recurrent Multiple Myeloma
genetic therapy
---
https://ansm.sante.fr/tableau-marr/ranibizumab
2024
false
false
false
France
French
risk management
Ranibizumab
Ranibizumab
patients guideline
intravitreal injections
patient education handout
package leaflet
ranibizumab
---
https://ansm.sante.fr/tableau-acces-derogatoire/yescarta-0-4-2-x-108-cellules-dispersion-pour-perfusion#
2024
false
false
false
France
French
axicabtagene ciloleucel
axicabtagene ciloleucel
biological products
Antineoplastic Agents, Immunological
Recurrent High Grade B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
adult
Refractory High Grade B-Cell Lymphoma
drug information
immunotherapy, adoptive
antigens, CD19
---
http://www.palliaguide.be/douleur-soins-palliatifs/
2024
false
false
false
Belgium
French
practice guideline
pain measurement
pain
analgesics, opioid
palliative care
acetaminophen
anti-inflammatory agents, non-steroidal
dipyrone
analgesics, non-narcotic
tramadol
codeine
morphine
oxycodone
hydromorphone
fentanyl
buprenorphine
---
https://www.cochrane.org/fr/CD003129/MUSKEL_quels-sont-les-benefices-et-les-risques-du-methotrexate-dans-le-traitement-de-larthrite-juvenile
2024
false
true
false
United Kingdom
France
treatment outcome
review of literature
french abstract
arthritis, juvenile
methotrexate
---
https://www.cochrane.org/fr/CD002203/CF_traitement-par-antibiotiques-macrolides-y-compris-lazithromycine-pour-les-personnes-atteintes-de
2024
false
true
false
United Kingdom
France
treatment outcome
azithromycin
infant, newborn
adult
child
pseudomonas aeruginosa
pseudomonas infections
meta-analysis
french abstract
macrolides
cystic fibrosis
anti-bacterial agents
---
https://ansm.sante.fr/tableau-acces-derogatoire/altuvoct
2024
false
false
false
France
French
Efanesoctocog Alfa
drug information
hemophilia A
hemorrhage
hemorrhage
---
https://www.has-sante.fr/jcms/p_3499784/fr/prolastin-alpha-1-antitrypsine-humaine-deficit-en-alpha-1-antitrypsine
2024
false
false
false
France
insurance, health, reimbursement
alfa1 antitrypsin
alpha 1-Antitrypsin
alpha 1-antitrypsin deficiency
Product containing only human alpha1 proteinase inhibitor in parenteral dose form
(medicinal product form)
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3499791/fr/altuvoct-efanesoctocog-alfa-hemophilie
2024
false
false
false
France
Efanesoctocog Alfa
hemophilia A
hemorrhage
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3499781/fr/ferinject-carboxymaltose-ferrique-carence-martiale
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
iron, parenteral preparations
injections, intravenous
infusions, intravenous
ferric carboxymaltose
ferric compounds
Iron Deficiencies
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3499775/fr/sialanar-bromure-de-glycopyrronium-sialorrhee-severe
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
Glycopyrronium
glycopyrrolate
sialorrhea
glycopyrronium
nervous system diseases
chronic disease
child
adolescent
administration, oral
pharmaceutical solutions
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3500260/fr/livmarli-maralixibat-syndrome-d-alagille
2024
false
false
false
France
Cholestatic pruritus (disorder)
treatment outcome
insurance, health, reimbursement
infant
child
administration, oral
pharmaceutical solutions
maralixibat chloride
Maralixibat Chloride
cholestatic pruritus in Alagille syndrome
evaluation of the transparency committee
alagille syndrome
maralixibat
---
https://www.has-sante.fr/jcms/p_3500387/fr/dupixent-dupilumab-dermatite-atopique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
dupilumab
injections, subcutaneous
adult
Adult atopic dermatitis (disorder)
evaluation of the transparency committee
dermatitis, atopic
dupilumab
---
https://www.has-sante.fr/jcms/p_3500390/fr/lepticur-chlorhydrate-de-tropatepine-syndrome-parkinsonien-induit-par-les-neuroleptiques
2024
false
false
false
France
Tropatepine hydrochloride (substance)
Parkinsonism caused by neuroleptic drug (disorder)
treatment outcome
insurance, health, reimbursement
tropatepine
administration, oral
tablets
-
evaluation of the transparency committee
parkinson disease, secondary
tropatepine
antipsychotic agents
---
https://www.cbip.be/fr/articles/4277?folia=4275
2024
false
false
false
Belgium
French
journal article
drug information
pulmonary disease, chronic obstructive
administration, inhalation
Chronic obstructive pulmonary disease exacerbation
comparative effectiveness research
glucocorticoids
adrenergic beta-2 receptor agonists
Long-Acting beta2-adrenergic receptor Agonist
long-acting anticholinergic
cholinergic antagonists
bronchodilator agents
---
https://ansm.sante.fr/tableau-marr/tafamidis
2024
false
false
false
France
French
risk management
tafamidis
administration, oral
guidelines for drug use
tafamidis
adult
pregnancy
breast feeding
tafamidis
Cardiac Amyloidosis
amyloidosis, hereditary, Transthyretin-Related
amyloidosis, hereditary, Transthyretin-Related
---
https://www.ema.europa.eu/en/medicines/human/EPAR/rezzayo
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Rezafungin
Rezafungin
rezafungin acetate
orphan drug production
drug approval
europe
antifungal agents
antifungal agents
adult
candidiasis, invasive
infusions, intravenous
risk management
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
Rezafungin Acetate
Rezafungin Acetate
aged
beta-(1,3)-D-glucan synthase
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/yesafili
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
aflibercept
aflibercept
aflibercept
biosimilar pharmaceuticals
---
https://www.ema.europa.eu/en/medicines/human/EPAR/inaqovi
2024
false
false
false
Netherlands
French
English
decitabine and cedazuridine drug combination
decitabine and cedazuridine drug combination
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
cedazuridine
cedazuridine
drug approval
europe
antimetabolites, antineoplastic
antimetabolites, antineoplastic
adult
leukemia, myeloid, acute
administration, oral
risk management
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
decitabine, combinations
drug evaluation, preclinical
Product containing precisely cedazuridine 100 milligram and decitabine 35 milligram/1
each conventional release oral tablet (clinical drug)
---
https://www.ema.europa.eu/en/medicines/human/EPAR/orserdu
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
elacestrant
elacestrant
elacestrant
postmenopause
drug approval
europe
selective estrogen receptor modulators
selective estrogen receptor modulators
breast neoplasms
breast neoplasms, male
Locally Advanced Estrogen Receptor-Positive Breast Carcinoma
Metastatic Estrogen Receptor-Positive Breast Carcinoma
HER2-Negative Breast Carcinoma
administration, oral
risk management
product surveillance, postmarketing
drug interactions
Activating ESR1 Gene Mutation
breast neoplasms
estrogen receptor alpha
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/ebglyss
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
lebrikizumab
lebrikizumab
lebrikizumab
drug approval
europe
dermatitis, atopic
adult
child
adolescent
injections, subcutaneous
risk management
product surveillance, postmarketing
aged
pregnancy
breast feeding
drug interactions
Interleukin-13
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/herwenda
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Trastuzumab
Trastuzumab
trastuzumab
biosimilar pharmaceuticals
---
https://www.ema.europa.eu/en/medicines/human/EPAR/aqumeldi
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
enalapril maleate
enalapril maleate
enalapril
---
https://www.ema.europa.eu/en/medicines/human/EPAR/jaypirca
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
pirtobrutinib
pirtobrutinib
pirtobrutinib
orphan drug production
---
https://www.ema.europa.eu/en/medicines/human/EPAR/degarelix-accord
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
degarelix
degarelix
degarelix
drugs, generic
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tyruko
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Natalizumab
Natalizumab
natalizumab
biosimilar pharmaceuticals
multiple sclerosis
drug approval
europe
infusions, intravenous
immunologic factors
immunologic factors
drug interactions
pregnancy
breast feeding
continuity of patient care
drug evaluation, preclinical
adult
integrin alpha4beta1
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tepkinly
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Epcoritamab
Epcoritamab
epcoritamab
orphan drug production
drug approval
europe
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
adult
lymphoma, large B-Cell, diffuse
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
recurrence
injections, subcutaneous
risk management
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
aged
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/lyfnua
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Gefapixant
Gefapixant
gefapixant
drug approval
europe
purinergic P2X3 receptor antagonists
purinergic P2X3 receptor antagonists
purinergic P2X receptor antagonists
purinergic P2X receptor antagonists
Chronic Cough
adult
pregnancy
breast feeding
drug interactions
administration, oral
risk management
product surveillance, postmarketing
Refractory chronic cough (disorder)
Unexplained chronic cough (disorder)
aged
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tevimbra
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tislelizumab
tislelizumab
tislelizumab
orphan drug production
drug approval
europe
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
Esophageal Squamous Cell Carcinoma
neoplasm metastasis
Metastatic Esophageal Squamous Cell Carcinoma
Unresectable Esophageal Squamous Cell Carcinoma
Refractory Esophageal Squamous Cell Carcinoma
adult
infusions, intravenous
risk management
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
---
https://www.ema.europa.eu/en/medicines/human/EPAR/enrylaze
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Asparaginase Erwinia chrysanthemi
Asparaginase Erwinia chrysanthemi
asparaginase
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tyenne
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tocilizumab
tocilizumab
tocilizumab
biosimilar pharmaceuticals
---
https://www.ema.europa.eu/en/medicines/human/EPAR/apretude
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
cabotegravir
cabotegravir
cabotegravir
---
https://www.ema.europa.eu/en/medicines/human/EPAR/talvey
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Talquetamab
Talquetamab
talquetamab
orphan drug production
multiple myeloma
Triple-Class Refractory Multiple Myeloma
Recurrent Multiple Myeloma
adult
drug approval
europe
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
injections, subcutaneous
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
---
https://ansm.sante.fr/actualites/obesite-quel-profil-dutilisation-de-wegovy-en-france-pendant-son-acces-precoce
2024
false
false
false
France
French
drug information
obesity
Wegovy
semaglutide
Product containing only semaglutide in parenteral dose form (medicinal product form)
drug utilization review
Glucagon-Like Peptide-1 Receptor Agonists
pharmacoepidemiology
france
drug utilization
---
https://sante.gouv.fr/soins-et-maladies/medicaments/professionnels-de-sante/autorisation-de-mise-sur-le-marche/la-liste-en-sus/article/referentiel-des-indications-des-specialites-pharmaceutiques-inscrites-sur-la
2024
false
false
false
France
French
directory
Formularies, Hospital as Topic
pharmacy service, hospital
pharmaceutical preparations
Clinical Indication
---
https://www.has-sante.fr/jcms/p_3501627/fr/skyrizi-risankizumab-maladie-de-crohn
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
infusions, intravenous
injections, subcutaneous
Interleukin Inhibitors
risankizumab
evaluation of the transparency committee
crohn disease
risankizumab
---
https://www.has-sante.fr/jcms/p_3501976/fr/cosentyx-secukinumab-rhumatisme-psoriasique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
secukinumab
injections, subcutaneous
Interleukin Inhibitors
adult
Interleukin-17
evaluation of the transparency committee
arthritis, psoriatic
secukinumab
---
https://www.cbip.be/fr/articles/4279?folia=4275
2024
false
false
false
Belgium
French
Dutch
journal article
eczema
child
emollients
---
https://ansm.sante.fr/informations-de-securite/paxlovid-nirmatrelvir-ritonavir-rappel-des-interactions-medicamenteuses-avec-certains-immunosuppresseurs-notamment-le-tacrolimus-pouvant-etre-fatales
2024
false
false
false
France
French
pharmacovigilance note
guidelines for drug use
drug interactions
nirmatrelvir and ritonavir drug combination
nirmatrelvir
immunosuppressive agents
tacrolimus
COVID-19 Drug Treatment
adult
nirmatrelvir and ritonavir
tacrolimus
---
https://ansm.sante.fr/actualites/decision-dautorisation-dimportation-parallele-accordee-le-21-03-2024-triflucan-40-mg-ml-poudre-pour-suspension-buvable
2024
false
false
false
France
French
drug information
fluconazole
legislation, pharmacy
spain
---
https://ansm.sante.fr/actualites/decision-dautorisation-dimportation-parallele-accordee-le-21-03-2024-suvreza-20-mg-10-mg-comprime-pellicule
2024
false
false
false
France
French
drug information
legislation, pharmacy
drug combinations
Ezetimibe
Rosuvastatin Calcium
rosuvastatin and ezetimibe
spain
---
https://ansm.sante.fr/actualites/decision-du-21-03-2024-cadre-de-prescription-compassionnelle-de-tacrolimus-0-1-pommade
2024
false
false
false
France
French
drug information
tacrolimus
administration, cutaneous
ointments
legislation, pharmacy
adult
child
adolescent
vitiligo
tacrolimus
---
https://ansm.sante.fr/tableau-acces-derogatoire/inspra-25-mg-comprime-pellicule
2024
false
false
false
France
French
Eplerenone
continuity of patient care
guidelines for drug use
adult
hyperaldosteronism
technical report
---
https://ansm.sante.fr/tableau-acces-derogatoire/omaveloxolone
2024
false
false
false
France
French
summary of product characteristics
package leaflet
insurance, health, reimbursement
Omaveloxolone
administration, oral
guidelines for drug use
adult
adolescent
friedreich ataxia
---
https://ansm.sante.fr/actualites/abrogation-de-certaines-autorisations-de-mise-sur-le-marche-de-generiques-de-tecfidera
2024
false
false
false
France
French
drug information
drugs, generic
Dimethyl Fumarate
legislation, pharmacy
europe
drug approval
dimethyl fumarate
legislation, drug
---
https://ansm.sante.fr/tableau-acces-derogatoire/danicopan
2024
false
false
false
France
French
drug information
danicopan
administration, oral
drug therapy, combination
Extravascular hemolysis (finding)
adult
paroxysmal nocturnal hemoglobinuria
hemolysis
danicopan
---
https://www.has-sante.fr/jcms/p_3482873/fr/cibinqo-abrocitinib-dermatite-atopique-da
2024
false
false
false
France
abrocitinib
treatment outcome
insurance, health, reimbursement
Janus Kinase Inhibitors
administration, oral
adult
evaluation of the transparency committee
dermatitis, atopic
abrocitinib
---
https://www.has-sante.fr/jcms/p_3486160/fr/jyseleca-filgotinib-rectocolite-hemorragique-rch
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
Janus Kinase Inhibitors
filgotinib
adult
evaluation of the transparency committee
colitis, ulcerative
filgotinib
---
https://www.has-sante.fr/jcms/p_3486233/fr/xeljanz-tofacitinib-arthrite-juvenile-idiopathique-aji
2024
false
false
false
France
Product containing only tofacitinib in oral dose form (medicinal product form)
tablets
pharmaceutical solutions
administration, oral
treatment outcome
insurance, health, reimbursement
child
adolescent
Polyarticular juvenile idiopathic arthritis
tofacitinib
evaluation of the transparency committee
arthritis, juvenile
Polyarticular Juvenile Idiopathic Arthritis
tofacitinib
---
https://www.has-sante.fr/jcms/p_3487097/fr/columvi-glofitamab-lymphome-diffus-a-grande-cellule-b-ldgcb
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
infusions, intravenous
Antineoplastic Agents, Immunological
lymphoma, large B-Cell, diffuse
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
glofitamab
evaluation of the transparency committee
glofitamab
---
https://www.has-sante.fr/jcms/p_3486120/fr/tibsovo-ivosidenib-cancer-des-voies-biliaires
2024
false
false
false
France
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
adult
treatment outcome
insurance, health, reimbursement
cholangiocarcinoma
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
administration, oral
antineoplastic agents
ivosidenib
evaluation of the transparency committee
ivosidenib
---
https://www.has-sante.fr/jcms/p_3487172/fr/botox-toxine-botulinique-type-a-blepharospasme-spasme-hemifacial-torticolis-spasmodique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
botulinum toxin
neuromuscular agents
evaluation of the transparency committee
hemifacial spasm
botulinum toxins, type A
blepharospasm
torticollis
Spasmodic Torticollis
---
https://www.has-sante.fr/jcms/p_3478093/fr/blincyto-blinatumomab-lal-en-echec-d-au-moins-2-traitements-avec-itk
2024
false
false
false
France
precursor cell lymphoblastic Leukemia-Lymphoma
leukemia, lymphocytic, acute, L2
B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
antineoplastic agents
blinatumomab
evaluation of the transparency committee
blinatumomab
---
https://www.has-sante.fr/jcms/p_3488172/fr/lynparza-olaparib-cancer-de-l-ovaire
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
olaparib
antineoplastic combined chemotherapy protocols
Bevacizumab/Olaparib Regimen
adult
Carcinoma, Ovarian Epithelial
Stage III Ovarian Cancer AJCC v6 and v7
Stage IV Ovarian Cancer AJCC v6 and v7
fallopian tube neoplasms
peritoneal neoplasms
administration, oral
evaluation of the transparency committee
olaparib
---
https://www.has-sante.fr/jcms/p_3481441/fr/ultibro-breezhaler-indacaterol/bromure-de-glycopyrronium-bronchopneumopathie-chronique-obstructive-bpco
2024
false
false
false
France
indacaterol
insurance, health, reimbursement
treatment outcome
drug combinations
indacaterol-glycopyrronium combination
adult
administration, inhalation
evaluation of the transparency committee
Glycopyrronium
pulmonary disease, chronic obstructive
---
https://www.has-sante.fr/jcms/p_3487178/fr/solu-medrol-methylprednisolone-corticoides
2024
false
false
false
France
injections, intravenous
injections, intramuscular
evaluation of the transparency committee
adrenal cortical hormone, nos
corticoids
methylprednisolone hemisuccinate
medrol
Methylprednisolone
glucocorticoids
---
https://www.has-sante.fr/jcms/p_3487169/fr/tagrisso-osimertinib-cancer-bronchique-non-a-petites-cellules-cbnpc
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
bronchial neoplasms
administration, oral
antineoplastic agents
osimertinib
adult
evaluation of the transparency committee
carcinoma, non-small-cell lung
osimertinib
---
https://ansm.sante.fr/tableau-marr/inhibiteur-de-la-c1-esterase-humaine
2024
false
false
false
France
French
risk management
guidelines for drug use
continuity of patient care
Human C1-Esterase Inhibitor
patients guideline
---
https://www.cbip.be/fr/articles/4238?folia=4237
2024
false
false
false
Belgium
French
journal article
obesity
treatment outcome
semaglutide
risks and benefits
Benefit-Risk assessment
cardiovascular diseases
---
https://www.has-sante.fr/jcms/p_3488409/fr/libtayo-cemiplimab-cancer-bronchopulmonaire-non-a-petites-cellules-cbnpc
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Antineoplastic Agents, Immunological
cemiplimab
antibodies, monoclonal, humanized
antineoplastic combined chemotherapy protocols
adult
platinum compounds
PD-L1 Positive
evaluation of the transparency committee
carcinoma, non-small-cell lung
cemiplimab
---
https://www.has-sante.fr/jcms/p_3488284/fr/caspofungine-tillomed-caspofungine-antimycotique-a-usage-systemique
2024
false
false
false
France
drugs, generic
infusions, intravenous
caspofungin
evaluation of the transparency committee
Caspofungin
antifungal agents
---
https://www.has-sante.fr/jcms/p_3488415/fr/jemperli-dostarlimab-cancer-de-l-endometre
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
dostarlimab
adult
mismatch repair deficient/microsatellite instability-high recurrent or advanced endometrial
cancer that has progressed
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
evaluation of the transparency committee
endometrial neoplasms
dostarlimab
---
https://www.has-sante.fr/jcms/p_3488635/fr/cabesol-clobetasol-psoriasis
2024
false
false
false
France
scalp dermatoses
administration, cutaneous
hair preparations
insurance, health, reimbursement
treatment outcome
glucocorticoids
clobetasol
Psoriasis of scalp (disorder)
evaluation of the transparency committee
clobetasol
psoriasis
---
https://www.has-sante.fr/jcms/p_3488641/fr/closalis-calcipotriol/betamethasone-psoriasis
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug combinations
betamethasone dipropionate, calcipotriol drug combination
calcipotriene
betamethasone-17,21-dipropionate
adult
calcipotriol, combinations
administration, cutaneous
ointments
Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1
gram and calcipotriol 50 microgram/1 gram conventional release cutaneous ointment
(clinical drug)
evaluation of the transparency committee
psoriasis
---
https://www.has-sante.fr/jcms/p_3488638/fr/conydix-ciclopirox-onychomycoses
2024
false
false
false
France
administration, topical
treatment outcome
insurance, health, reimbursement
antifungal agents
Medicated Nail Lacquer Dosage Form
ciclopirox
evaluation of the transparency committee
Ciclopirox
onychomycosis
---
https://www.has-sante.fr/jcms/p_3490351/fr/lytgobi-futibatinib-cholangiocarcinome
2024
false
false
false
France
futibatinib
treatment outcome
insurance, health, reimbursement
adult
Intrahepatic Cholangiocarcinoma
antineoplastic agents
Locally Advanced Intrahepatic Cholangiocarcinoma
Metastatic Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
FGFR2 Gene Rearrangement
FGFR2 Gene Fusion Positive
Cancer Progression
administration, oral
evaluation of the transparency committee
cholangiocarcinoma
futibatinib
---
https://www.has-sante.fr/jcms/p_3490357/fr/budesonide-teva-sante-budesonide-corticoide
2024
false
false
false
France
administration, oral
treatment outcome
insurance, health, reimbursement
Modified-release Hard Capsule Dosage Form
crohn disease
colitis, microscopic
budesonide
evaluation of the transparency committee
glucocorticoids
budesonide
corticoids
---
https://www.has-sante.fr/jcms/p_3490695/fr/casgevy-exagamglogene-autotemcel-thalassemie-dependante-des-transfusions-tdt
2024
false
false
false
France
biological products
insurance, health, reimbursement
treatment outcome
Transfusion Dependent Beta Thalassemia
beta-Thalassemia
exagamglogene autotemcel
adolescent
young adult
infusions, intravenous
adoptive transfer
evaluation of the transparency committee
Exagamglogene Autotemcel
---
https://www.has-sante.fr/jcms/p_3490839/fr/cufence-trientine-dichlorhydrate-maladie-de-wilson
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
chelating agents
trientine
adult
adolescent
child
evaluation of the transparency committee
trientine hydrochloride
hepatolenticular degeneration
trientine
---
https://www.has-sante.fr/jcms/p_3490834/fr/trodelvy-sacituzumab-govitecan-cancer-du-sein
2024
false
false
false
France
adult
treatment outcome
insurance, health, reimbursement
infusions, intravenous
sacituzumab govitecan
HER2/Neu Negative
Hormone Receptor Positive
evaluation of the transparency committee
breast neoplasms
sacituzumab govitecan
---
https://www.cochrane.org/fr/CD001797/NEUROMUSC_les-immunoglobulines-intraveineuses-sont-elles-sures-et-efficaces-pour-les-personnes-atteintes-de
2024
false
United Kingdom
France
French
meta-analysis
polyradiculoneuropathy, chronic inflammatory demyelinating
immunoglobulins, intravenous
treatment outcome
french abstract
---
https://ansm.sante.fr/tableau-acces-derogatoire/tacrolimus#
2024
false
false
false
France
French
tacrolimus
drug information
administration, cutaneous
vitiligo
---
https://www.has-sante.fr/jcms/p_3503277/fr/evkeeza-evinacumab-hypercholesterolemie-homozygote-familiale
2024
false
false
false
France
child
treatment outcome
insurance, health, reimbursement
Homozygous Familial Hypercholesterolemia
antibodies, monoclonal
evinacumab
guidelines for drug use
package leaflet
summary of product characteristics
Product containing only evinacumab in parenteral dose form (medicinal product form)
infusions, intravenous
evaluation of the transparency committee
evkeeza
evinacumab
---
https://www.has-sante.fr/jcms/p_3502273/fr/polystyrene-sulfonate-de-sodium-substipharm-polystyrene-sulfonate-de-sodium-hyperkaliemie
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
hyperkalemia
chelating agents
administration, oral
administration, rectal
polystyrene sulfonate
evaluation of the transparency committee
polystyrene sulfonic acid
polystyrenes
polystyrene sulfonic acid, homopolymer, sodium salt
---
https://www.has-sante.fr/jcms/p_3503249/fr/elrexfio-elranatamab-myelome-multiple
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
antibodies, monoclonal
adult
multiple myeloma
package leaflet
summary of product characteristics
guidelines for drug use
recurrence
Triple-Class Refractory Multiple Myeloma
Recurrent Multiple Myeloma
Progressive Neoplastic Disease
evaluation of the transparency committee
Elranatamab
---
https://www.has-sante.fr/jcms/p_3505636/fr/rybrevant-amivantamab-cancer-bronchique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
carboplatin
amivantamab
Antineoplastic Agents, Immunological
bispecific monoclonal antibodies
advanced non-small cell lung cancer with activating epidermal growth factor receptor
exon 20 insertion mutations
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
Activating EGFR Exon 20 Mutation
EGFR Exon 20 Insertion Mutation
Pemetrexed
adult
package leaflet
summary of product characteristics
guidelines for drug use
infusions, intravenous
evaluation of the transparency committee
bronchial neoplasms
amivantamab-vmjw
---
https://www.has-sante.fr/jcms/p_3505761/fr/retsevmo-selpercatinib-cancer-bronchique-non-a-petites-cellules
2024
false
false
false
France
bronchial neoplasms
adult
treatment outcome
insurance, health, reimbursement
antineoplastic agents
administration, oral
selpercatinib
package leaflet
summary of product characteristics
guidelines for drug use
advanced RET fusion-positive non-small cell lung cancer
RET Fusion Positive
carcinoma, non-small-cell lung
Advanced Lung Non-Small Cell Carcinoma
evaluation of the transparency committee
selpercatinib
carcinoma, non-small-cell lung
---
https://www.has-sante.fr/jcms/p_3470375/fr/camzyos-mavacamten-cardiomyopathie-hypertrophique-obstructive
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
mavacamten
administration, oral
New York Heart Association Class II
New York Heart Association Class III
adult
symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic
cardiomyopathy (oHCM)
evaluation of the transparency committee
cardiomyopathy, hypertrophic
mavacamten
Cardiomyopathy, Hypertrophic Obstructive
---
https://www.has-sante.fr/jcms/p_3503160/fr/zilbrysq-zilucoplan-sodique-myasthenie
2024
false
false
false
France
zilucoplan
treatment outcome
insurance, health, reimbursement
myasthenia gravis, generalized
myasthenia gravis
adult
Anti-acetylcholine receptor antibody positivity
evaluation of the transparency committee
zilucoplan
myasthenia gravis
---
https://www.has-sante.fr/jcms/p_3505844/fr/litfulo-ritlecitinib-pelade
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
adolescent
administration, oral
ritlecitinib
Janus Kinase Inhibitors
immunosuppressive agents
evaluation of the transparency committee
Ritlecitinib
alopecia areata
---
https://www.has-sante.fr/jcms/p_3505740/fr/lojuxta-lomitapide-hypercholesterolemie-familiale-homozygote
2024
false
false
false
France
Lomitapide Mesylate
Homozygous Familial Hypercholesterolemia
child
adolescent
evaluation of the transparency committee
lomitapide
Lomitapide Mesylate
mesylates
---
https://www.cbip.be/fr/elderlymeds
2024
false
false
false
Belgium
French
Dutch
aged
pharmaceutical preparations
drug prescriptions
guidelines for drug use
---
https://ansm.sante.fr/actualites/avis-de-lansm-du-11-03-2024-sur-le-medicament-keytruda-dans-le-cadre-dune-demande-daap
2024
false
false
false
France
French
treatment outcome
pembrolizumab
Antineoplastic Agents, Immunological
drug information
Resectable Lung Non-Small Cell Carcinoma
carcinoma, non-small-cell lung
neoplasm recurrence, local
risk
pembrolizumab
---
https://ansm.sante.fr/tableau-acces-derogatoire/blenrep
2024
false
false
false
France
French
infusions, intravenous
drug information
antibodies, monoclonal, humanized
belantamab mafodotin
Antineoplastic Agents, Immunological
---
https://www.has-sante.fr/jcms/p_3505841/fr/ventizolve-naloxone-antidote-des-surdoses-aux-opioides
2024
false
false
false
France
administration, intranasal
treatment outcome
insurance, health, reimbursement
Naloxone Hydrochloride Dihydride
narcotic antagonists
emergency treatment
adult
naloxone
evaluation of the transparency committee
Opiate Overdose
naloxone
antidotes
---
https://ansm.sante.fr/tableau-marr/dronedarone
2024
false
false
false
France
French
risk management
continuity of patient care
Dronedarone
Dronedarone
dronedarone
administration, oral
guidelines for drug use
patient education handout
atrial fibrillation
Persistent Atrial Fibrillation
Paroxysmal Atrial Fibrillation
anti-arrhythmia agents
anti-arrhythmia agents
---
https://ansm.sante.fr/tableau-acces-derogatoire/tigilanol-tiglate
2024
false
false
false
France
French
Tigilanol Tiglate
drug information
Intratumoral use
---
https://ansm.sante.fr/tableau-acces-derogatoire/flunatop
2024
false
false
false
France
French
administration, oral
summary of product characteristics
drug information
flunarizine
---
https://ansm.sante.fr/tableau-acces-derogatoire/a-cq-100
2024
false
false
false
France
French
summary of product characteristics
drug information
chloroquine diphosphate
administration, oral
malaria, vivax
---
https://ansm.sante.fr/tableau-acces-derogatoire/vorasidenib
2024
false
false
false
France
French
drug information
administration, oral
vorasidenib
glioma
antineoplastic agents
---
https://ansm.sante.fr/tableau-acces-derogatoire/fruzaqla
2024
false
false
false
France
French
administration, oral
fruquintinib
antineoplastic agents
fruquintinib
VEGFR Tyrosine Kinase Inhibitor
summary of product characteristics
drug information
colorectal neoplasms
neoplasm metastasis
---
https://ansm.sante.fr/tableau-acces-derogatoire/irenat
2024
false
false
false
France
French
administration, oral
pharmaceutical solutions
sodium perchlorate
summary of product characteristics
package leaflet
drug information
Iodine-Induced Hyperthyroidism
Hypothyroidism due to iodide organification defect (disorder)
---
https://www.ema.europa.eu/en/medicines/human/EPAR/elrexfio
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
europe
drug approval
Elranatamab
Elranatamab
multiple myeloma
recurrence
Progressive Neoplastic Disease
Triple-Class Refractory Multiple Myeloma
adult
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
Recurrent Multiple Myeloma
antibodies, monoclonal
antibodies, monoclonal
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
injections, subcutaneous
bispecific monoclonal antibodies
bispecific monoclonal antibodies
Immune Effector Cell Associated Neurotoxicity Syndrome
Elranatamab
Cytokine Release Syndrome
continuity of patient care
---
https://www.ema.europa.eu/en/medicines/human/EPAR/zilbrysq
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
zilucoplan
zilucoplan
zilucoplan
adult
myasthenia gravis
myasthenia gravis, generalized
generalised myasthenia gravis with anti-acetylcholine receptor antibody
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
Anti-acetylcholine receptor antibody positivity
myasthenia gravis
risk management
injections, subcutaneous
drug therapy, combination
---
https://ansm.sante.fr/actualites/tramadol-moins-de-comprimes-dans-les-boites-pour-un-meilleur-usage
2024
false
false
false
France
French
tramadol
drug information
---
https://www.has-sante.fr/jcms/p_3506762/fr/balversa-erdafitinib-carcinome-urothelial
2024
false
false
false
France
erdafitinib
administration, oral
Product containing only erdafitinib in oral dose form (medicinal product form)
evaluation of the transparency committee
erdafitinib
erdafitinib
Erdafitinib
---
https://www.has-sante.fr/jcms/p_3508311/fr/sotatercept-sotatercept-hypertension-arterielle-pulmonaire
2024
false
false
false
France
ACE-011
adult
drug therapy, combination
Pulmonary arterial hypertension WHO functional class II
Pulmonary arterial hypertension WHO functional class III
guidelines for drug use
orphan drug production
evaluation of the transparency committee
Pulmonary Arterial Hypertension
sotatercept
---
https://www.has-sante.fr/jcms/p_3471694/fr/orkambi-lumacaftor/ivacaftor-mucoviscidose
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
lumacaftor, ivacaftor drug combination
drug combinations
ivacaftor
lumacaftor
ivacaftor and lumacaftor
infant
administration, oral
evaluation of the transparency committee
cystic fibrosis
---
https://ansm.sante.fr/tableau-marr/crizotinib
2024
false
false
false
France
French
patients guideline
patient education handout
drug information
risk management
Crizotinib
Crizotinib
continuity of patient care
crizotinib
vision disorders
adult
child
---
https://ansm.sante.fr/actualites/modification-des-conditions-de-prescription-et-de-delivrance-de-certaines-biotherapies-utilisees-dans-le-traitement-de-maladies-inflammatoires-chroniques
2024
false
false
false
France
French
guidelines for drug use
injections, subcutaneous
Interleukin Inhibitors
immunosuppressive agents
biological therapy
general practice
antibodies, monoclonal
immunoconjugates
Tumor Necrosis Factor Inhibitors
Chronic inflammatory disorder (disorder)
---
https://www.has-sante.fr/jcms/p_3506437/fr/rubraca-rucaparib-cancer-de-l-ovaire
2024
false
false
false
France
fallopian tube neoplasms
peritoneal neoplasms
treatment outcome
insurance, health, reimbursement
administration, oral
rucaparib
evaluation of the transparency committee
rucaparib
ovarian neoplasms
Rucaparib Camsylate
---
https://www.has-sante.fr/jcms/p_3508868/fr/acide-tranexamique-tillomed-acide-tranexamique-antifibrinolytique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, intravenous
adult
adolescent
child
hemorrhage
hemorrhage due to fibrinolysis
drugs, generic
tranexamic acid
evaluation of the transparency committee
antifibrinolytic agents
tranexamic acid
---
https://www.has-sante.fr/jcms/p_3508907/fr/folinate-de-calcium-kalceks-folinate-de-calcium-hydrate-oncologie
2024
false
false
false
France
drugs, generic
treatment outcome
insurance, health, reimbursement
calcium folinate
injections, intramuscular
infusions, intravenous
antidotes
methotrexate
Drug-Related side effects and adverse reactions
Methotrexate Toxicity
adult
child
antineoplastic combined chemotherapy protocols
Leukovorin rescue (procedure)
evaluation of the transparency committee
leucovorin
Leucovorin, Calcium (1:1) Salt
---
https://www.has-sante.fr/jcms/p_3508898/fr/bendamustine-accord-bendamustine-hematologie
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
bendamustine
infusions, intravenous
antineoplastic agents, alkylating
Stage C Chronic Lymphocytic Leukemia
Stage B Chronic Lymphocytic Leukemia
lymphoma, Non-Hodgkin
leukemia, lymphocytic, chronic, B-Cell
multiple myeloma
DS Stage II Multiple Myeloma
DS Stage III Multiple Myeloma
evaluation of the transparency committee
Bendamustine Hydrochloride
---
https://www.has-sante.fr/jcms/p_3509116/fr/junaliza-atorvastatine/ezetimibe-hypolipidemiants-en-association
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
Ezetimibe
Atorvastatin
atorvastatin calcium
atorvastatin and ezetimibe
hypercholesterolemia
non-familial primary hypercholesterolemia
Familial hypercholesterolemia - heterozygous (disorder)
Mixed Hyperlipidemia
adult
evaluation of the transparency committee
drug combinations
hypolipidemic agents
---
https://ansm.sante.fr/tableau-acces-derogatoire/sotatercept
2024
false
false
false
France
French
sotatercept
recombinant fusion proteins
Pulmonary Arterial Hypertension
drug information
---
https://ansm.sante.fr/tableau-marr/natalizumab-1
2024
false
false
false
France
French
Natalizumab
risk management
Natalizumab
natalizumab
guidelines for drug use
patient education handout
continuity of patient care
Drug-Related side effects and adverse reactions
opportunistic infections
leukoencephalopathy, progressive multifocal
immunologic factors
immunologic factors
multiple sclerosis
---
https://www.cochrane.org/fr/CD007024/ADDICTN_le-disulfirame-en-tant-que-medicament-pour-le-traitement-de-la-dependance-la-cocaine
2024
false
United Kingdom
France
French
meta-analysis
cocaine-related disorders
treatment outcome
disulfiram
french abstract
---
https://ansm.sante.fr/tableau-marr/adalimumab
2024
false
false
false
France
French
Adalimumab
risk management
continuity of patient care
drug information
adult
child
patient education handout
---
https://ansm.sante.fr/actualites/cannabis-medical-point-detape-sur-la-derniere-annee-de-lexperimentation-et-larrivee-de-medicaments-a-base-de-cannabis
2024
false
false
false
France
French
drug information
medical marijuana
Medical cannabis therapy
---
https://ansm.sante.fr/tableau-marr/fentanyl-6
2024
false
false
false
France
French
fentanyl
Fentanyl Citrate
risk management
administration, sublingual
guidelines for drug use
fentanyl
patients guideline
adult
breakthrough pain
drug prescriptions
narcotics
Cancer Pain
---
https://www.has-sante.fr/jcms/p_3449778/fr/crysvita-burosumab-hypophosphatemie-liee-au-fgf23
2024
false
false
false
France
French
evaluation of the transparency committee
burosumab
---
https://www.has-sante.fr/jcms/p_3495394/fr/takhzyro-lanadelumab-angioedeme-hereditaire
2024
false
false
false
France
French
insurance, health, reimbursement
lanadelumab
evaluation of the transparency committee
child
angioedemas, hereditary
Hereditary angioedema attack
lanadelumab
treatment outcome
guidelines for drug use
Product containing precisely lanadelumab 150 milligram/1 milliliter conventional release
solution for injection (clinical drug)
---
https://ansm.sante.fr/tableau-acces-derogatoire/tak-755
2024
false
false
false
France
French
Apadamtase Alfa
congenital thrombotic thrombocytopenic purpura
enzyme replacement therapy
summary of product characteristics
package leaflet
guidelines for drug use
ADAMTS13 Protein
purpura, thrombotic thrombocytopenic
child
adolescent
adult
---
https://www.has-sante.fr/jcms/p_3497014/fr/dovato-dolutegravir/lamivudine-antiretroviraux
2024
false
false
false
France
drug combinations
treatment outcome
insurance, health, reimbursement
lamivudine
dolutegravir sodium
dolutegravir
Dolutegravir Sodium/Lamivudine
hiv infections
HIV-1
adult
adolescent
lamivudine and dolutegravir
administration, oral
evaluation of the transparency committee
anti-retroviral agents
---
https://www.has-sante.fr/jcms/p_3497032/fr/azelastine-chlorhydrate-/-fluticasone-propionate-eg-chlorhydrate-d-azelastine-/-propionate-de-fluticasone-rhinite-allergique
2024
false
false
false
France
drug combinations
treatment outcome
insurance, health, reimbursement
rhinitis, allergic, seasonal
fluticasone, combinations
administration, intranasal
histamine H1 antagonists, non-sedating
anti-inflammatory agents
evaluation of the transparency committee
azelastine hydrochloride
Fluticasone
rhinitis, allergic, perennial
Fluticasone Propionate
azelastine
---
https://www.has-sante.fr/jcms/p_3497011/fr/jardiance-empagliflozine-maladie-renale-chronique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
empagliflozin
drug therapy, combination
administration, oral
Sodium-Glucose Transporter 2 Inhibitors
chronic kidney diseases
evaluation of the transparency committee
empagliflozin
---
https://www.has-sante.fr/jcms/p_3492882/fr/alvesco-ciclesonide-asthme
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
glucocorticoids
administration, inhalation
ciclesonide
evaluation of the transparency committee
asthma
ciclesonide
---
https://www.has-sante.fr/jcms/p_3497026/fr/mircera-methoxy-polyethylene-glycol-epoetine-beta-anemie-symptomatique-associee-a-l-insuffisance-renale-chronique-chez-les-enfants-ages-de-3-mois-a-moins-de-18-ans
2024
false
false
false
France
infant
adolescent
treatment outcome
insurance, health, reimbursement
hematinics
methoxy polyethylene glycol-epoetin beta
Anemia of chronic renal failure (disorder)
evaluation of the transparency committee
continuous erythropoietin receptor activator
polyethylene glycols
anemia
erythropoietin
methoxy polyethylene glycol-epoetin beta
renal insufficiency, chronic
child
---
https://www.has-sante.fr/jcms/p_3497047/fr/xerava-eravacycline-tetracyclines
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
eravacycline
Complicated intra-abdominal infection
complicated intra-abdominal infections
infusions, intravenous
adult
xerava
anti-bacterial agents
Product containing only eravacycline in parenteral dose form (medicinal product form)
evaluation of the transparency committee
tetracyclines
eravacycline
---
https://www.has-sante.fr/jcms/p_3497164/fr/omvoh-mirikizumab-rectocolite-hemorragique
2024
false
false
false
France
mirikizumab
treatment outcome
insurance, health, reimbursement
adult
gastrointestinal agents
infusions, intravenous
injections, subcutaneous
Interleukin Inhibitors
Interleukin-23
evaluation of the transparency committee
colitis, ulcerative
mirikizumab
---
https://www.has-sante.fr/jcms/p_3496898/fr/hydagelan-hydromorphone-douleurs
2024
false
false
false
France
Hydromorphone Hydrochloride
treatment outcome
insurance, health, reimbursement
adult
child
adolescent
infusions, subcutaneous
injections, subcutaneous
infusions, intravenous
injections, intravenous
analgesics, opioid
hydromorphone
evaluation of the transparency committee
hydromorphone
Cancer Pain
---
https://www.has-sante.fr/jcms/p_3498565/fr/sogroya-somapacitan-deficit-en-hormone-de-croissance
2024
false
false
false
France
sogroya
child
adolescent
adult
treatment outcome
insurance, health, reimbursement
hormone replacement therapy
injections, subcutaneous
orphan drug production
failure to thrive
Product containing only somapacitan in parenteral dose form (medicinal product form)
somapacitan
evaluation of the transparency committee
somapacitan
Growth Hormone Deficiency
human growth hormone
---
https://www.has-sante.fr/jcms/p_3498130/fr/prevymis-letermovir-antiviral
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
infusions, intravenous
letermovir
chemoprevention
kidney transplantation
cytomegalovirus infections
adult
living donors
Cytomegalovirus antibody detected in serum (finding)
Cytomegalovirus antibody not detected in serum (finding)
Kidney Donor
evaluation of the transparency committee
letermovir
antiviral agents
---
https://www.has-sante.fr/jcms/p_3498124/fr/kevzara-sarilumab-polyarthrite-rhumatoide
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
sarilumab
drug therapy, combination
methotrexate
adult
injections, subcutaneous
evaluation of the transparency committee
arthritis, rheumatoid
sarilumab
---
https://www.has-sante.fr/jcms/p_3498146/fr/myozyme-alglucosidase-alfa-maladie-de-pompe-deficit-en-glucosidase-acide
2024
false
false
false
France
GAA protein, human
adult
adolescent
child
treatment outcome
insurance, health, reimbursement
enzyme replacement therapy
infusions, intravenous
alglucosidase alfa
glycogen storage disease type II, infantile
adult glycogen storage disease type II
Glycogen storage disease type II late onset (disorder)
evaluation of the transparency committee
glycogen storage disease type ii
alglucosidase alfa
---
https://www.has-sante.fr/jcms/p_3473151/fr/fiche-bum-dupixent-fasenra-nucala-tezspire-et-xolair-dans-le-traitement-de-l-asthme-severe
2024
false
false
false
France
dupilumab
benralizumab
mepolizumab
tezepelumab
other systemic drugs for obstructive airway diseases
adult
child
drug therapy, combination
Severe persistent asthma (disorder)
adolescent
Respiratory corticosteroid (substance)
adrenergic beta-2 receptor agonists
guidelines for drug use
Omalizumab
asthma
---
https://www.has-sante.fr/jcms/p_3498562/fr/adtralza-tralokinumab-dermatite-atopique-chez-l-adulte-et-l-adolescent-a-partir-de-12-ans
2024
false
false
false
France
tralokinumab
injections, subcutaneous
adolescent
adult
dermatitis, atopic
Adult atopic dermatitis (disorder)
evaluation of the transparency committee
tralokinumab
---
https://www.has-sante.fr/jcms/p_3415645/fr/qinlock-ripretinib-tumeurs-stromales-gastro-intestinales
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
Advanced Gastrointestinal Stromal Tumor
Refractory Malignant Gastrointestinal Stromal Tumor
antineoplastic agents
ripretinib
administration, oral
evaluation of the transparency committee
gastrointestinal stromal tumors
ripretinib
---
https://www.has-sante.fr/jcms/p_3498741/fr/takhzyro-lanadelumab-angiooedeme-hereditaire
2024
false
false
false
France
antibodies, monoclonal, humanized
treatment outcome
insurance, health, reimbursement
angioedemas, hereditary
child
lanadelumab
Product containing precisely lanadelumab 150 milligram/1 milliliter conventional release
solution for injection (clinical drug)
Hereditary angioedema attack
evaluation of the transparency committee
lanadelumab
---
https://www.has-sante.fr/jcms/p_3468175/fr/imfinzi-durvalumab-cancer-des-voies-biliaires
2024
false
false
false
France
Cisplatin/Durvalumab/Gemcitabine Regimen
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
cisplatin
Gemcitabine
Unresectable Biliary Tract Carcinoma
Metastatic Biliary Tract Carcinoma
neoplasm metastasis
Antineoplastic Agents, Immunological
durvalumab
adult
guidelines for drug use
evaluation of the transparency committee
biliary tract cancer
biliary tract neoplasms
durvalumab
---
https://www.has-sante.fr/jcms/p_3498750/fr/keytruda-pembrolizumab-carcinome-a-cellules-renales
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
antineoplastic combined chemotherapy protocols
clear cell renal cell carcinoma
Lenvatinib/Pembrolizumab Regimen
Advanced Clear Cell Renal Cell Carcinoma
infusions, intravenous
Antineoplastic Agents, Immunological
pembrolizumab
evaluation of the transparency committee
pembrolizumab
carcinoma, renal cell
---
https://ansm.sante.fr/tableau-marr/tocilizumab-1
2024
false
false
false
France
French
risk management
tocilizumab
infusions, intravenous
injections, subcutaneous
guidelines for drug use
tocilizumab
tocilizumab
patient education handout
continuity of patient care
tocilizumab
---
https://ansm.sante.fr/tableau-marr/sarilumab
2024
false
false
false
France
French
risk management
continuity of patient care
drug information
injections, subcutaneous
antibodies, monoclonal, humanized
sarilumab
patients guideline
---
https://ansm.sante.fr/tableau-acces-derogatoire/lynparza-100-mg-et-150-mg-comprimes-pellicules
2023
false
false
false
France
French
drug information
olaparib
administration, oral
olaparib
breast neoplasms
HER2-Negative Breast Carcinoma
---
https://ansm.sante.fr/tableau-acces-derogatoire/kimozo-40-mg-ml-suspension-buvable#
2023
false
false
false
France
French
administration, oral
antineoplastic agents, alkylating
Temozolomide
child
neuroblastoma
summary of product characteristics
package leaflet
guidelines for drug use
Refractory Neuroblastoma
Recurrent Neuroblastoma
High Risk Neuroblastoma
glioblastoma multiforme
anaplastic astrocytoma
Recurrent Childhood Anaplastic Astrocytoma
Refractory Anaplastic Astrocytoma
medulloblastoma
Recurrent Childhood Medulloblastoma
Refractory Medulloblastoma
sarcoma, ewing
Recurrent Ewing Sarcoma
Refractory Ewing Sarcoma
rhabdomyosarcoma
Recurrent Childhood Rhabdomyosarcoma
Refractory Childhood Rhabdomyosarcoma
---
https://ansm.sante.fr/tableau-marr/daratumumab
2023
false
false
false
France
French
guideline
patient education handout
risk management
daratumumab
daratumumab
Laboratory test related to immunohematology (procedure)
Laboratory test interference
immunologic tests
hematologic tests
---
https://ansm.sante.fr/tableau-acces-derogatoire/velcade-1-mg-poudre-pour-solution-injectable
2023
false
false
false
France
French
drug information
Bortezomib
injections, intravenous
Immunoglobulin Light-chain Amyloidosis
Non-amyloid monoclonal immunoglobulin deposition disease
---
https://ansm.sante.fr/tableau-acces-derogatoire/xalkori
2023
false
false
false
France
French
drug information
administration, oral
Crizotinib
antineoplastic agents
protein kinase inhibitors
capsules
pharmaceutical solutions
child
infant
lymphoma, large-cell, anaplastic
Childhood Anaplastic Large Cell Lymphoma, ALK-Positive
crizotinib
MET Exon 14 Mutation
Locally Advanced Lung Non-Small Cell Carcinoma
adult
Metastatic Lung Non-Small Cell Carcinoma
carcinoma, non-small-cell lung
continuity of patient care
---
https://ansm.sante.fr/tableau-acces-derogatoire/imcivree#
2023
false
false
false
France
French
setmelanotide
adult
adolescent
child
obesity
obesity
bardet-biedl syndrome
continuity of patient care
drug monitoring
product surveillance, postmarketing
setmelanotide
injections, subcutaneous
drug information
---
https://ansm.sante.fr/tableau-acces-derogatoire/scemblix-20-mg-40-mg-comprimes-pellicules
2023
false
false
false
France
French
asciminib
administration, oral
guidelines for drug use
asciminib
protein kinase inhibitors
summary of product characteristics
package leaflet
leukemia, lymphocytic, acute, L2
leukemia, lymphocytic, acute, L2
mutation
T315I mutation
leukemia, myelogenous, chronic, bcr-abl positive
leukemia, myelogenous, chronic, bcr-abl positive
---
https://ansm.sante.fr/tableau-marr/avalglucosidase-alfa
2023
false
false
false
France
French
guidelines for drug use
risk management
Infusion-Related Reaction
medication errors
Avalglucosidase Alfa
infusions, intravenous
home infusion therapy
continuity of patient care
enzyme replacement therapy
GAA protein, human
avalglucosidase alfa
monitoring, immunologic
glycogen storage disease type ii
---
https://ansm.sante.fr/tableau-acces-derogatoire/dupixent
2023
false
false
false
France
French
summary of product characteristics
package leaflet
injections, subcutaneous
dupilumab
adult
Prurigo nodularis (disorder)
guidelines for drug use
prurigo
dupilumab
dermatitis, atopic
child
---
https://ansm.sante.fr/tableau-acces-derogatoire/vyvgart
2023
false
false
false
France
French
efgartigimod alfa
infusions, intravenous
myasthenia gravis, generalized
Acetylcholine receptor antibody (substance)
Anti-acetylcholine receptor antibody positivity
efgartigimod alfa
generalised myasthenia gravis with anti-acetylcholine receptor antibody
drug information
---
https://ansm.sante.fr/tableau-acces-derogatoire/tezspire#
2023
false
false
false
France
French
tezepelumab
asthma
adult
adolescent
guidelines for drug use
evaluation of the transparency committee
continuity of patient care
injections, subcutaneous
forms
tezepelumab
---
https://ansm.sante.fr/tableau-acces-derogatoire/teclistamab
2023
false
false
false
France
French
drug information
Teclistamab
adult
multiple myeloma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
summary of product characteristics
package leaflet
antibodies, monoclonal
Antineoplastic Agents, Immunological
teclistamab
---
https://ansm.sante.fr/tableau-acces-derogatoire/nexviadyme-100-mg-poudre-pour-solution-a-diluer-pour-perfusion
2023
false
false
false
France
French
summary of product characteristics
package leaflet
infusions, intravenous
Avalglucosidase Alfa
glycogen storage disease type ii
guidelines for drug use
---
https://www.has-sante.fr/jcms/p_3343465/fr/jardiance-empagliflozine-insuffisance-cardiaque
https://has-sante.fr/jcms/p_3343475/fr/decision-n-2022-0310/dp/sem-du-3-juin-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-jardiance
2023
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
guidelines for drug use
heart failure
empagliflozin
---
https://www.has-sante.fr/jcms/p_3348751/fr/carvykti-ciltacabtagene-autoleucel-myelome-multiple
2023
false
false
false
France
Ciltacabtagene Autoleucel
Ciltacabtagene Autoleucel
treatment outcome
insurance, health, reimbursement
adult
recurrence
immunotherapy, adoptive
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
package leaflet
summary of product characteristics
Chimeric Antigen Receptor T-Cell Therapy
Recurrent Multiple Myeloma
Triple-Class Refractory Multiple Myeloma
ciltacabtagene autoleucel
evaluation of the transparency committee
multiple myeloma
---
https://ansm.sante.fr/tableau-marr/onasemnogene-abeparvovec
2023
false
false
false
France
French
guidelines for drug use
risk management
Zolgensma
onasemnogene abeparvovec
infusions, intravenous
patients guideline
child
spinal muscular atrophies of childhood
onasemnogene abeparvovec-xioi
biological products
recombinant fusion proteins
---
https://ansm.sante.fr/tableau-marr/agalsidase-beta
2023
false
false
false
France
French
risk management
agalsidase beta
guidelines for drug use
patients guideline
infusions, intravenous
enzyme replacement therapy
fabry disease
continuity of patient care
home health nursing
---
https://ansm.sante.fr/tableau-marr/methoxyflurane
2023
false
false
false
France
French
risk management
methoxyflurane
administration, inhalation
guidelines for drug use
methoxyflurane
methoxyflurane
Drug-Related side effects and adverse reactions
emergency treatment
pain
wounds and injuries
Post-traumatic pain
---
